BLR1/CXCR5 expression in B-cell tumors and the non-neoplastic T cells in these patients
| Tumor Type . | Cases Tested . | %-Positive B Cells (CD19-positive) . | %-Positive Non-Neoplastic T Cells (CD3-positive) . |
|---|---|---|---|
| L1 or L2 ALL | 8/8 | 95 | 74 |
| Burkitt's lymphoma/L3 ALL | 1/1 | 91 | 69 |
| CLL | 13/13 | 100 | 57 |
| Prolymphocytic leukemia | 1/1 | 99 | 17 |
| Hairy cell leukemia | 1/1 | 100 | 28 |
| Mantle cell lymphoma | 1/1 | 66 | 34 |
| Follicular lymphoma | 2/2 | 100 | 98 |
| Marginal zone lymphoma | 2/2 | 85 | 35 |
| Lymphoplasmacytic lymphoma | 1/1 | 91 | 74 |
| Reactive lymph node | 1/1 | 90 | 83 |
| Peripheral blood | 8/8 | 91 | 15 |
| Tumor Type . | Cases Tested . | %-Positive B Cells (CD19-positive) . | %-Positive Non-Neoplastic T Cells (CD3-positive) . |
|---|---|---|---|
| L1 or L2 ALL | 8/8 | 95 | 74 |
| Burkitt's lymphoma/L3 ALL | 1/1 | 91 | 69 |
| CLL | 13/13 | 100 | 57 |
| Prolymphocytic leukemia | 1/1 | 99 | 17 |
| Hairy cell leukemia | 1/1 | 100 | 28 |
| Mantle cell lymphoma | 1/1 | 66 | 34 |
| Follicular lymphoma | 2/2 | 100 | 98 |
| Marginal zone lymphoma | 2/2 | 85 | 35 |
| Lymphoplasmacytic lymphoma | 1/1 | 91 | 74 |
| Reactive lymph node | 1/1 | 90 | 83 |
| Peripheral blood | 8/8 | 91 | 15 |
Flow cytometric detection using 51505.111 CXCR5 monoclonal antibody with gating on the lymphocyte population by forward and side scatter properties.